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Summary A virus is a pathogenic organism that causes a number of infectious diseases in
humans. The oral cavity is the site at which viruses enter and are excreted from the human
body. Herpes simplex virus type 1 (HSV-1) produces the primary infectious disease, gingivostom-
atitis, and recurrent disease, labial herpes. HSV-1 is one of the most extensively investigated
viruses used for cancer therapy. In principle, HSV-1 infects epithelial cells and neuronal cells
and exhibits cytotoxicity due to its cytopathic effects on these cells. If the replication of the
virus occurs in tumor cells, but not normal cells, the virus may be used as an antitumor agent.
Therefore, HSV-1 genes have been modified by genetic engineering, and in vitro and in vivo
studies with the oncolytic virus have demonstrated its efficiency against head and neck cancer
including oral cancer. The oncolytic abilities of other viruses such as adenovirus and reovirus
have also been demonstrated. In clinical trials, HSV-1 is the top runner and is now available
for the treatment of patients with advanced melanoma. Thus, melanoma in the oral cavity is
the target of oncolytic HSV-1. Oncolytic virotherapy is a hopeful and realistic modality for the
treatment of oral cancer.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese Association for Dental
Science. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Contents
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Oncolyc virus
Replicaon-compet ent
Non-patho genic to humans  
Tumor cells
Replicaon in tumor cells
Producon of progeny viruses
Normal cells
Destrucon  of tumor  cells,  
but not  normal  cells
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i. Introduction
ead and neck cancer accounts for 6% of all malignancies
orldwide. Oral cancer is included in head and neck can-
er, is the fifteenth most common malignancy globally, and
ccounts for approximately 1% of all malignancies in Japan.
ost cases of oral cancer are squamous cell carcinoma
SCC). Surgery, radiation, chemotherapy and the combina-
ion of these modalities are common therapeutic methods
o treat patients. The therapeutic effects of chemoradio-
herapy using cisplatin markedly improved 5-year overall
urvival over radiotherapy alone; however, survival rates in
dvanced cases are still low [1,2]. A recent aspect is the
ntroduction of molecular target therapy using an antibody
gainst the epidermal growth factor receptor (EGFR), cetux-
mab. The treatment of locoregional advanced head and
eck cancer with concomitant high-dose radiotherapy plus
etuximab has improved locoregional control and reduced
ortality [3], although cisplatin-based chemoradiotherapy
emains the standard of care until equivalence with radio-
herapy plus cetuximab is reproducibly demonstrated [4].
Immunotherapy with biological response modifiers
BRMs) including OK-432 (picibanil) and BCG has been used to
nhance antitumor immunity and biological responses have
een reported; however, their effects on tumor immunity
ave been non-specific [5]. Tumor antigen-specific vaccina-
ions have since been perceived as a potentially effective
pproach to improve outcomes by mobilizing antitumor
mmunity and reversing immune escape in cancer patients.
hase 1 studies using survivin-derived peptides and p53 pep-
ide vaccines for patients with head and neck cancer were
ound to be safe and achieved moderate clinical outcomes
6,7]. On the other hand, efforts to restore latent antitu-
or immunity have focused on antibody-based interventions
argeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and
rogrammed cell death protein 1 (PD-1) on T cells and
ts principal ligand (PD-L1) on tumor cells. The immune
heckpoint inhibitor to either PD-1 or PD-L1 has produced
ignificant antitumor activity with markedly less toxicity
han the CTLA-4 inhibitor. In clinical trials on these immune
heckpoint inhibitors, positive responses were observed in
atients with melanoma, renal cancer, lung cancer, bladderPlease cite this article in press as: Yura Y. Presage of oncolyt
Japanese Dental Science Review (2016), http://dx.doi.org/10.
ancer, and head and neck cancer [8,9].
Another recent advance in cancer treatments is the use
f viruses that destroy tumors, i.e., oncolytic viruses. Since
ome viruses exhibit oncolytic abilities, attempts to use
s
t
l
pigure 1 Schematic representation of selective killing effects
f oncolytic viruses on tumor cells.
iruses as antitumor agents were made in the 1950s [10]. In
apan, the mumps virus was used and clinical effects were
bserved in 37 out of 90 terminal cancer patients; however,
urther clinical studies were not performed [11]. On the
ther hand, a virus is the most reliable vector to transfer
uman genes into deficient individuals. In 1990, a clinical
rial on gene therapy was initiated to transfer the adeno-
ine deaminase (ADA) gene into the T cells of two children
ith severe combined immunodeficiency using a retrovirus
o deliver the gene [12]. Gene therapy was also applied to
he treatment of cancer. For example, the wild-type tumor
uppressor gene p53 carrying a retrovirus or adenovirus was
ntroduced into lung cancer patients in whom the p53 gene
as mutated in order to restore the function of wild-type
53 [13,14]. Repeated intratumoral injections of adenovirus
Ad-p53) were tolerated well, resulted in the transgene
xpression of wild-type p53, and appeared to mediate anti-
umor activity in a subset of patients with advanced lung
ancer. Viruses for gene therapy are generally replication-
estricted in order to prevent the endless spread of viral
nfection in the body. A virus infects appropriate target cells,
ntroduces genes into the cells, and its replication is then
erminated. Target cells that acquire a tumor suppression
ene are destroyed by the action of the gene, whereas cells
evoid of the infection survive, and its effect on cancer is
radually lost, resulting in the failure of this therapy. This
s a limitation of replication-restricted viruses. As a nextic virotherapy for oral cancer with herpes simplex virus.
1016/j.jdsr.2016.10.001
tep, replication-competent viruses were reconsidered as a
ool to destroy a larger number of tumor cells by inocu-
ated viruses and progeny viruses (Fig. 1). This concept was
roposed by Martuza, a doctor of neurosurgery [15]. Mar-
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Figure 2 Schematic representation of the genomic structure of oncolytic HSV-1.
TRL, terminal repeat of the L component; UL, the L component; IRL, internal repeat of the L component; IRS, internal repeat of the
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factor; ICP, infected cell protein.
tuza et al. attempted to destroy tumors in a glioma model
using herpes simplex virus type 1 (HSV-1) in which the thymi-
dine kinase (TK) gene was deleted by genetic engineering.
This is the first published study to treat tumors with a mod-
ified replication-competent virus and the method was later
called oncolytic virotherapy. HSV-1 frequently infects the
oral mucosa and produces the primary infectious disease,
gingivostomatitis, and recurrent disease, labial herpes. HSV-
1 is one of the most extensively investigated viruses used
for cancer therapy [16—20]. In this review, the development
of viruses for use as a treatment of head and neck cancer
including oral cancer is discussed with a focus on oncolytic
HSV-1.
2. Development of an oncolytic virus
2.1. Genetic engineering of HSV-1
Since Martuza et al. published their work indicating that
an engineered HSV-1 is applicable to the treatment of
brain tumors, a number of viruses were considered to be
oncolytc viruses for solid tumors. The major oncolytic DNA
viruses are HSV, adenovirus, and vaccinia virus, and RNA
viruses are coxsackie virus, reovirus, measles virus, New-
castle disease virus (NDV), and vesicular stomatitis virus
(VSV) [16—23]. Oncolytic viruses may infect and replicate
in tumor cells to produce progeny viruses, which is fol-
lowed by the destruction of host tumor cells. If the progeny
virus infects inherently susceptible cells and induces infec-
tious disease, the treatment is not acceptable because the
spread of infection must be limited to tumors. The initial
HSV-1 vector tested was a TK gene-deficient mutant of HSV-
1 [15]. However, the TK gene coded by the L component
(UL) 23 of the HSV-1 genome is essential for the selec-
tive effects of the anti-herpes virus drug, aciclovir [24];Please cite this article in press as: Yura Y. Presage of oncolyt
Japanese Dental Science Review (2016), http://dx.doi.org/10.
therefore, viral genes other than TK must be modified in
subsequently developed oncolytic HSV-1s. Since the  134.5
gene was found to be responsible for the neurovirulence of
HSV-1 [25], HSV-1 vectors that were deficient in the  134.5
t
a
pmponent; GM-CSF, granulocyte macrophage colony-stimulating
ene were constructed. They were R3616, R489, HSV1716,
V1020, and G207 derived from wild-type HSV-1 strain F [26]
Fig. 2). When the  134.5 gene was deleted, the ability of
he virus to induce encephalitis was lost, even if the virus
as directly injected into the brain. Moreover, the  134.5
ene has been shown to play a major role in the selective
argeting of tumor cells in HSV-1-mediated virotherapy. An
nfection with HSV-1 induces an interferon reaction, which
ctivates double-stranded RNA-dependent protein kinase
PKR). PKR phosphorylates eukaryotic initiation factor 2  
eIF-2), which is essential for the translation of mRNA,
esulting in the total shutdown of protein synthesis. The
SV-1  134.5 gene acts as a phosphatase accessory factor
hat recruits protein phosphatase 1 in order to dephospho-
ylate eIF-2. As a consequence, protein synthesis continues
nimpeded in cells in which HSV-1 expresses the  134.5
ene. Thus, if the  134.5 gene is deleted, the virus does
ot replicate in normal cells in which PKR is activated
fter infection by the virus. However, it was found that this
utant had the ability to replicate in tumor cells. The mech-
nisms responsible are not yet clear; however, RAS signals
nd down-stream mitogen-activated protein kinase (MAPK)
inase (MEK) may be activated in tumor cells constitution-
lly. These activated kinases block the activation of PKR
y the HSV-1 infection such that the  134.5 gene-deficient
irus replicates in tumor cells, but not normal cells [27,28].
he efficiency of  134.5 gene-deficient HSV-1 against tumors
as demonstrated in basic and clinical studies without the
nduction of encephalitis [26,29—31]. Furthermore, another
ene that encodes ribonucleotide reductase (RR) was modi-
ed to improve the specificity of viruses against tumor cells.
R is essential for viral replication and is provided by the
ost cell or virus itself; therefore, RR-dependent HSV-1 is
ermitted to replicate in proliferating tumor cells with RR
ctivity only at a high level. HSV-1 with double mutations in
he   34.5 gene and UL39 gene encoding infected cell pro-ic virotherapy for oral cancer with herpes simplex virus.
1016/j.jdsr.2016.10.001
1
ein (ICP) 6 (RR) was subsequently constructed to decrease
dverse effects; however, the killing effect of the virus was
artly impaired [32]. It exerted cytotoxic effects on tumor
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Table 1 Oncolytic HSV-1 investigated for its oncolytic ability to head and neck cancer.
Name Modification Clinical trial (HNSCC) References
R849  134.5 deleted, with LacZ [39,64]
HSV1716  134.5 deleted Phase I [49]
NV1020 One copy of  134.5 deleted
HSV-1/HSV-2 intertypic
recombinant
[31]
G207  134.5 and ICP6 (UL39) deleted [33]
G47 delta  134.5, ICP6 (UL39), and ICP47
(US12) deleted
[44]
Talimogene laherparepvec
(T-Vec); OncoVEXGM-CSF
Imlygic (drug name)
134.5 and ICP47 (US12)
deleted, with human GM-CSF
Phase I/II [52]
OncoVEX GALV/CD 134.5 and ICP47 (US12)
deleted, with the GALV protein
and CD
[35]
HF10 Mutations (glycoproteins,
UL56)
Phase I [54]
RH2 Mutations (gB, gD),  134.5
deleted R849/HF recombinant
[40,41]
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virus; CD, cytosine deaminase.
ells and spared the normal mucosa when injected into the
umors of patients with head and neck cancer [33] (Table 1).
.2. Fusogenic HSV-1
everal viruses have been shown to destroy their tar-
et cells through multinucleated syncytial formation, a
rocess involving membrane fusion between infected and
n-infected cells. The viral components that contribute to
yncytial formation are mainly fusogenic membrane gly-
oproteins (FMGs). In order to efficiently spread the viral
nfection around the surrounding tumor cells, the FMG gene
rom gibbon ape leukemia virus (GALV) was inserted into
he HSV-1 genome. The virus caused strong cell membrane
usion and significantly increased the potency of viral oncol-
sis [34]. HSV-1 expressing cytosine deaminase (CD) and FMG
as reported to exert its lytic effects on head and neck
CC cells at a relatively low viral dose, whereas prodrug
onversion by CD did not necessarily enhance therapy at
oses that caused efficient cytotoxicity [35]. HF10, a clone
f the spontaneously occurring and highly attenuated labo-
atory strain HF, induced extensive cell fusion and formed
yncytia composed of large multinucleate cells [36]. HF10
as less virulent than wild-type HSV-1 in mice and did not
nduce encephalitis when injected into a peripheral site in
ice; however, a high-dose intracerebral injection induced
ncephalitis. The genome of HF10 has large deletions at both
nds of the L-region, an extensive genomic rearrangement,
nd it lacks the expression of UL56 and latency-associated
ranscript (LAT). The glycoprotein mutations responsible for
ell fusion and a UL56 deletion have been implicated inPlease cite this article in press as: Yura Y. Presage of oncolyt
Japanese Dental Science Review (2016), http://dx.doi.org/10.
ts low neurovirulence [37]. Since no foreign genes were
ntroduced into the genome, HF10 has an advantage over
iruses with genetic engineering in that permission has been
btained from the Japanese government for clinical studies
o
i
a
bacrophage colony-stimulating factor; GALV, gibbon ape leukemia
38]. A recombinant between R849, a  134.5 gene-deficient
SV-1 in which the LacZ gene was inserted, and HF, the
arental virus of HF10, was subsequently produced [39,40].
his recombinant HSV-1 RH2 is deficient in the  134.5 gene
nd has more mutations than wild-type viruses; the full
equences of the viral genome have been published [41].
ariations in the genes glycoprotein B (gB) and glycoprotein
(gD) are considered to be responsible for the fusogenic
roperty of this virus. RH2 replicates efficiently, produces
arge syncytia, and destroys human oral SCC cells [40]. It
as also found to suppress the growth of oral SCC xenografts
n nude mice without any pathological features in animals.
. Antitumor immunity
ancer immunotherapy has wide appeal because of its hypo-
hetical ability to eradicate residual or metastatic tumors
hat are difficult to manage by conventional treatments. The
eneration of whole tumor vaccines through tumor destruc-
ion in vivo has the potential to release the entire reservoir
f tumor antigens in their native forms and configurations. In
ddition to the tumorcidal effects of viruses, oncolytic virus-
ediated tumor destruction may provide an in situ source of
umor antigens to stimulate antitumor immunity. This spe-
ific feature of oncolytic viruses that is responsible for tumor
mmunity was reported in the 1990s. An intratumoral injec-
ion of oncolytic HSV-1 into murine colorectal carcinoma or
euroblastoma induced a tumor-specific immune response in
ynergistic mice that subsequently contributed to a signifi-
ant reduction in the size of contralateral non-inoculated
umors or established tumors in the brain [42]. A previ-ic virotherapy for oral cancer with herpes simplex virus.
1016/j.jdsr.2016.10.001
us study reported that fusogenic HSV-1 Synco-2D directly
nduced the cytolysis of tumor cells by syncytial formation
nd was considered to induce strong antitumor immunity,
ecause virus-uninjected local and metastatic lung tumors
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Oncolytic virotherapy for oral cancer
were markedly smaller than those in control mice [43]. A
novel oncolytic HSV-1 was subsequently produced in which
the  134.5 gene was deleted to provide selective tumor cell
proliferation, whereas the ICP 47 encoded by the S com-
ponent (US)12 gene of the HSV-1 genome was deleted in
order to enhance the antitumor response by antigen pre-
sentation and tumor cell killing through the up-regulation
of US11, which occurs following this mutation. G47 delta is
a mutant that contains three mutations, i.e.,  134.5, ICP6,
and ICP47. Its antitumor effects on human nasopharyngeal
carcinoma have been demonstrated in vitro and in vivo [44].
Furthermore, the gene of human granulocyte macrophage
colony-stimulating factor (GM-CSF) was inserted into the
HSV-1 vector backbone with the deletions of the  134.5 and
ICP47 (US12) genes [45]. GM-CSF is a potent immune stimula-
tor that promotes the differentiation of progenitor cells into
dendritic cells. The combination of GM-CSF with oncolytic
therapy may be particularly effective because cell death
accompanying virus replication serves to release tumor anti-
gens efficiently, which is required for GM-CSF-enhanced
immune responses. The HSV-1 vector with GM-CSF was ini-
tially named OncoVEXGM-CSF and was changed to talimogene
laherparepvec (T-Vec); its drug name is Imlygic (Fig. 2). The
treatment of disseminated peritoneal tumors with HF10 has
been shown to induce specific antitumor immune responses
[36]. The enhancing effects of R849/HF recombinant RH2
on tumor immunity were also demonstrated using a synergic
mouse model. Two tumors were produced on the back of the
C3H mouse and RH2 was injected into one tumor while the
contralateral tumor was left untreated. Although the sup-
pression of RH2-injected tumors was significantly greater
than that of uninjected tumors in the treated group, the
suppression of contralateral tumors was also greater in the
treated group than in the untreated group. Immune cell
infiltration, particularly, CD8+T cells played a major role in
this immune response [46]. Furthermore, cell death with
immunogenic potential, i.e., immunogenic cell death, was
also demonstrated in RH2-infected SCC cells [47].
4. Clinical study
4.1. Adverse effects
Since viruses have been shown to effectively reduce tumor
volumes in vivo, clinical trials have been undertaken using
adenovirus, HSV-1, coxsackie virus, reovirus, HSV, vac-
cinia virus, and VSV. Adenovirus, reovirus, and HSV have
been used in clinical studies for head and neck cancer
[16,20,21,23,48,49]. In a phase 1 study with HSV-1 G207
for recurrent malignant glioma, side effects were limited to
mild to moderate febrile reactions and localized erythema-
tous/inflammatory reactions at the injected sites of tumors
[50]. While commonly referred to as influenza-like symp-
toms, side effects are generally milder, but may be more
robust in patients who were seronegative for the parental
viral species at their first dose or when a high viral dose
is given by an intravenous route [23]. Safety issues withPlease cite this article in press as: Yura Y. Presage of oncolyt
Japanese Dental Science Review (2016), http://dx.doi.org/10.
oncolytic agents are mostly the same as those for live atten-
uated viral vaccines, and this is the general direction toward
which regulatory requirements are moving, albeit with con-
siderable country-to-country variations.
t
p
c
nherapy with oncolytic HSV-1 as reported by Harrington et al.
52].
.2. HSV-1 talimogene laherparepvec (T-Vec)
hile case reports have described significant responses to
ncolytic viruses in patients with disseminated diseases,
nly a small number of phase II/III trials have been pub-
ished to date [51,52]. The most recent of these and the
rst trail on oncolytic therapy to show its tangible bene-
ts is the phase III trial on HSV-1 T-Vec [53]. In this trial,
atients with treated/untreated unresectable stage IIIB/C
r stage IV melanoma were randomized 2:1 to receive intra-
umoral T-Vec or subcutaneous recombinant GM-CSF. Among
36 patients, the durable responsible rate was significantly
igher with T-Vec (16.3%) than with GM-CSF (2.1%). The over-
ll response rate was also higher in the T-Vec arm (26.4%)
han in the GM-CSF arm (5.7%). Median overall survival (OS)
as 23.3 months with T-Vec and 18.9 months with GM-CSF
P = 0.051). The most common adverse events with T-Vec
ere fatigue, chills, and pyrexia. T-Vec was effective, par-
icularly in untreated patients or those with stage IIIB, IIIC,
r IV1a disease. The clinical effects of T-Vec were also inves-
igated in combination with radiotherapy and cisplatin in
hase I/II study for patients with head and neck cancer in
ntreated stage III/IV [52] (Fig. 3). Seventeen patients were
nrolled. Patients received chemoradiotherapy (70Gy in 35
ractions with concomitant cisplatin 100mg/m2 on days 1,
2, and 43) and dose-escalating T-Vec by an intratumoral
njection on days 1, 22, 43, and 64. In this study, the intratu-
oral injection means an injection of T-Vec into metastatic
ymph nodes. Patients underwent neck dissection 6—8 weeks
fter the end of chemoradiotherapy. Locoregional control
as achieved in all patients, with a 76.5% relapse-free rate.
isease-specific survival was 82.4% at a median follow-up of
9 weeks (range, 19—40 months).
.3. HSV-1 HF10
F10 was demonstrated to be effective as an oncolytic agent
sing various murine tumor models, including melanoma,
etastatic breast cancer, bladder cancer, ovarian cancer,
arcoma, and colorectal cancer [18]. An intratumoral injec-ic virotherapy for oral cancer with herpes simplex virus.
1016/j.jdsr.2016.10.001
ion of HF10 was performed in a small number of Japanese
atients with recurrent breast cancer and head and neck
ancer without significant adverse effects. Metastatic skin
odules (lymph node metastasis) of head and neck cancer
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ere injected with HF10 once a day for 3 days. HF10 repli-
ated in the tumors, spread well in the tumor nodules, and
aused cell death in a large population of tumor cells [54].
n a phase 1 clinical trial for unresectable pancreatic can-
er, HF10 was injected intratumorally 3 times and exhibited
ome therapeutic potential. Tumor responses were classi-
ed as stable disease in 3 patients, a partial response in 1
atient, and progressive disease in 2 patients [55].
. New combination therapy
.1. Oncolytic virus and immune checkpoint
nhibitors
ntibodies targeting CTLA-4 and PD-1/PDL-1 are already
sed clinically for a range of malignancies, including
elanoma, and have had very positive effects. Melanoma
ntigen-specific vaccines have been evaluated in early phase
linical trials in adjuvant settings and were found to increase
he expression of PD-1 at the injection site. Similarly, there
s emerging evidence to show that oncolytic viruses regulate
he expression of PD1/PDL-1 in cancer cells, thereby provid-
ng a strong rational for combination therapy with immune
heckpoint inhibitors. The combination of anti-PD-1 and
eovirus led to longer survival than that with either agent
lone [56]. An anti-PD-1 antibody treatment down-regulated
egulatory T cell activity and increased effectiveness of NK-
ell-mediated lysis in malignant cells infected with reovirus.
n a phase I trial, the anti-CTLA-4 monoclonal antibody, ipil-
mumab, was combined with a poxvirus-based vaccine in
atients with castrate-resistant prostate cancer [57]. The
ide effect profile did not appear to differ significantly over
ingle agent therapy with ipilimumab. Most recently, encour-
ging findings have been reported from combination T-Vec
ith an anti-CTLA-4 antibody [58]. Ongoing T-Vec studies
nclude evaluations in the safety and efficacy of T-Vec plus
pilimumab versus ipilimumab alone and T-Vec plus pem-
rolizumab (anti-PD-1) versus pembrolizumab alone [23].
.2. A specific reagent to enhance the replication
f oncolytic HSV-1
ertain agents have been shown to induce the differen-
iation of malignant cells [59]. Tumor cells committed to
ifferentiate lose their ability to proliferate and prop-
gate when transplanted into animals. Hexamethylene
isacetamide (HMBA), a compound structurally related to
imethyl sulfoxide, was found to induce the differentia-
ion of erythroleukemia cells [60] and has been tested in
atients with refractory solid tumors [61]. HMBA is of inter-
st because it enhances the replication of wild-type HSV-1
n SCC cells and the addition of the compound facilitated
he reactivation of HSV-1 or HSV-2 in animal models [62,63].
he replication of  134.5 gene-deficient HSV-1 R849 in oral
CC cells was also enhanced in the presence of HMBA in oral
CC cells. In an animal study, the growth of nude mousePlease cite this article in press as: Yura Y. Presage of oncolyt
Japanese Dental Science Review (2016), http://dx.doi.org/10.
umors was markedly suppressed by R849 in combination
ith HMBA and the survival of co-treated animals was signif-
cantly longer than that of animals treated with R849 only.
MBA enhances the antitumor activity of an inoculated virus PRESS
Y. Yura
hrough the expression of immediate early genes without
ncreasing its toxicity [64]. It may be useful as an enhancing
gent for oncolytic therapy with HSV-1 in cancer patients.
. Conclusion
n oncolytic virotherapy, there are many hurdles that must
till be overcome. They include selective virus replication in
umor cells, efficient virus delivery and intratumoral spread,
timulation of antitumor immunity, immune-mediated clear-
nce of virion particles from patient body, limited ability
f pre-clinical tumor model systems to actually predict
he efficacy, and environmental viral shedding. Neverthe-
ess, the mechanisms by which oncolytic HSV-1 exerts its
ntitumor effects are completely different from those of
onventional and recent therapies with chemotherapeutic
gents, radiation, peptide vaccines, and monoclonal anti-
odies targeting EGFR, CTLA-4, and PD-1/PD-L1; it induces
ell lysis by viral replication in the tumor and releases
umor antigens to potentiate tumor immunity. In phase III
linical trials, oncolytic HSV-1 showed specific antitumor
mmunity and clinical responses in a significant fraction of
elanoma patients. The synergistic and/or additive effects
f oncolytic viruses have been demonstrated in combination
ith conventional modes of therapy. Based on encourag-
ng evidence supporting the safety and potential efficacy of
ncolytic viruses, there is a significant chance that viruses
ay become an entirely new modality for the treatment of
ral cancer.
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